ArticlePharmaceutical biology2026
Comparative cardioprotective effects of Kuanxiong Aerosol and its individual components in a rat model of acute myocardial infarction.
Article in Pharmaceutical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Effects of Kuanxiong aerosol for preventing acute mountain sickness: an exploratory small-sample randomized, placebo-controlled trial.Frontiers in physiology · 2026Article
- Kuanxiong aerosol protects against coronary microvascular dysfunction through improving angiogenesis via HIF-1α-ITGAX axis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextKuanxiong Aerosol (KXA), composed of volatile oils from sandalwood (
objectiveWe investigated the chemical composition, dose-dependent efficacy, and cardioprotective effects of KXA and its individual components in a rat acute myocardial infarction (AMI) model. MATERIALS AND
methodsKXA and its components were characterized using GC-MS. AMI was induced in rats by left anterior descending (LAD) ligation. Animals were pretreated with low-dose (120 µL/kg) or high-dose (200 µL/kg) KXA, its individual components (120 µL/kg), or isosorbide mononitrate (ISMN; 5 mg/kg). Cardioprotective effects were assessed
resultsLow-dose KXA provided significant cardioprotection, improving ST-segment elevation, infarct size, histopathology, hemodynamic, and biochemical markers, with efficacy comparable or more pronounced to ISMN. In contrast, high-dose KXA was less effective. Sandalwood and asarum oils were the primary anti-ischemic agents, while galangal oil, pepper oil, and borneol provided complementary anti-fibrotic and hemodynamic support. However, individual components or high doses exhibited limited efficacy and potential adverse effects. DISCUSSION AND
conclusionsKXA's cardioprotection stems from the synergistic action of its components targeting ischemia, fibrosis, inflammation, and cardiac dysfunction. This study provides evidence supporting the cardioprotective potential of low-dose, multi-component KXA, indicating that such balanced formulations may offer broader benefits than high-dose or single-agent approaches. Further research is needed to elucidate the molecular mechanisms and refine the formulation for clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.